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Systemic sclerosis (SSc) is a rare connective tissue disease characterized by three 
pathogenetic hallmarks: vasculopathy, dysregulation of the immune system, and 
fibrosis. A particular feature of SSc is the increased frequency of some types of malig­
nancies, namely breast, lung, and hematological malignancies. Moreover, SSc may 
also be a paraneoplastic disease, again indicating a strong link between cancer and 
scleroderma. The reason of this association is still unknown; therefore, we aimed at 
investigating whether particular genetic or epigenetic factors may play a role in promo­
ting cancer development in patients with SSc and whether some features are shared 
by the two conditions. We therefore performed a gene expression profiling of peripheral 
blood mononuclear cells (PBMCs) derived from patients with limited and diffuse SSc, 
showing that the various classes of genes potentially linked to the pathogenesis of 
SSc (such as apoptosis, endothelial cell activation, extracellular matrix remodeling, 
immune response, and inflammation) include genes that directly participate in the 
development of malignancies or that are involved in pathways known to be associ­
ated with carcinogenesis. The transcriptional analysis was then complemented by a 
complex network analysis of modulated genes which further confirmed the presence 
of signaling pathways associated with carcinogenesis. Since epigenetic mechanisms, 
such as microRNAs (miRNAs), are believed to play a central role in the pathogenesis 
of SSc, we also evaluated whether specific cancer­related miRNAs could be dereg­
ulated in the serum of SSc patients. We focused our attention on miRNAs already 
found upregulated in SSc such as miR­21­5p, miR­92a­3p, and on miR­155­5p, miR 
126­3p and miR­16­5p known to be deregulated in malignancies associated to SSc, 
i.e., breast, lung, and hematological malignancies. miR­21­5p, miR­92a­3p, miR­
155­5p, and miR­16­5p expression was significantly higher in SSc sera compared to 
healthy controls. Our findings indicate the presence of modulated genes and miRNAs 
that can play a predisposing role in the development of malignancies in SSc and are 
important for a better risk stratification of patients and for the identification of a better 
individualized precision medicine strategy.
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Table 1 | Clinical and demographic features of the patients enrolled in the 
study.
Demographic and clinical features systemic sclerosis patients
lssc Diffuse cutaneous ssc
Patients 15 15
Male/female 2/13 1/15
Mean age (years) 56 ± 15 54 ± 12
Laboratory findings ANA 14 (93%) 15 (100)
Anti­centromere 9 (60%) 3 (20%)
Scl­70 1 (6%) 11 (73%)
Lung involvement Interstitial disease 4 (26%) 8 (53%)
Pulmonary arterial 
hypertension
1 (6%) 2 (13%)
Skin involvement mRSS 8 ± 3 14 ± 8
Digital ulcers 5 (33%) 7 (46%)
Video Capillaroscopy Early 1 (6%) 4 (26%)
Active 8 (53%) 5 (33%)
Late 6 (40%) 6 (40%)
Kidney involvement 0 (0%) 1 (6%)
Gastro­intestinal involvement 9 (60%) 14 (93%)
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inTrODUcTiOn
Systemic sclerosis (SSc) is a rare, chronic disease characterized 
by three pathogenetic hallmarks: vasculopathy, dysregulation of 
the immune system, and increased extracellular matrix deposi-
tion in the skin and internal organs, leading to extended fibrosis 
and to a remarkable heterogeneity in clinical features and course 
of the disease, resulting in high morbidity and mortality (1).
Several environmental factors alongside genetic susceptibil-
ity and epigenetic mechanisms contribute to the onset of the 
disease (2–5).
Increased frequency of a few types of cancer, namely breast, 
lung, and hematologic malignancies in SSc has been reported 
(6), and it seems to be associated with the presence of particular 
autoantibodies (7). Moreover, it is worthwhile mentioning that 
SSc may also be a paraneoplastic disease (8, 9), indicating a strong 
link between cancer and scleroderma.
Given the high incidence of tumors in patients with SSc, we 
wanted to assess whether this phenomenon may be supported by 
a particular gene modulation that can favor cancer development 
in patients with SSc. Thus, we analyzed transcriptional profiles 
of peripheral blood mononuclear cells (PBMCs) obtained from 
patients with SSc to evaluate the presence of modulated genes that 
are involved in signaling pathways associated with malignancy. 
Moreover, through a complex network analysis, we verified which 
pathways could play a pivotal role in cancer development in SSc 
patients.
Besides environmental and genetic factors, epigenetic mecha-
nisms, such as microRNAs (miRNAs), are believed to play a 
central role in the pathogenesis of the disease.
microRNAs are a class of small non-coding RNAs that bind 
3’ untranslated region of messenger RNAs (mRNAs), negatively 
regulating target gene expression by either the repression of 
translation or degradation of target mRNAs (10). miRNAs 
are considered an important class of epigenetics regulators in 
many basic cellular processes as well as in the vast majority of 
diseases, including cancer and autoimmunity (11, 12). Little is 
known about the role of dysregulated expression of miRNAs in 
the pathogenesis of SSc (13). An altered expression of profibrotic 
and/or antifibrotic miRNAs has been suggested as an impor-
tant factor in the development of fibrosis in SSc patients (14). 
Moreover, increased evidence suggests that serum miRNA levels 
may be promising biomarkers for the diagnosis, prognosis, and 
therapeutic approach in SSc (15). Serum levels of miR-21 and 
miR-92a have been found significantly higher in SSc samples 
compared to normal controls (16, 17). Their function is impli-
cated in inflammation, in regulation of immune cells (18) and in 
favoring fibrosis (16, 17).
Since particular miRNAs have been associated with malignan-
cies, we aimed at evaluating whether transcriptional profiles and 
dysregulation of particular miRNAs are shared by cancer and SSc.
MaTerials anD MeThODs
Patients
We enrolled 30 patients affected by SSc, attending the Unit of 
Autoimmune Disease at the University Hospital of Verona, and 
30 sex and age matched healthy controls. All patients fulfilled 
the ACR/Eular classification criteria for SSc (19). The distinction 
between limited (lSSc) and diffuse cutaneous SSc (dSSc) was 
performed according to the criteria proposed by LeRoy et al. (20). 
Fifteen of the 30 patients were affected by lSSc and 15 by dSSc. 
The clinical and demographic features of the patients enrolled in 
the study are summarized in Table 1.
Samples obtained from 10 patients with lSSc, 10 patients with 
dSSc, and 10 healthy controls were used for the gene expression 
analysis, whereas samples obtained from all the patients and 
controls were used for the microRNA study. Blood samples were 
collected from patients with active disease and in the absence of 
immunosuppressive therapies.
A written informed consent was obtained by all the partici-
pants to the study and the study protocol was approved by the 
Ethical Committee of the Azienda Ospedaliera Universitaria 
Integrata di Verona. All the investigations have been per-
formed according to the principles contained in the Helsinki 
declaration.
gene expression analysis
Blood samples were collected in BD Vacutainer K2EDTA tubes 
using a 21-gage needle. PBMC were obtained upon stratification 
on Lympholyte® cell separation density gradient (Cedarlane, 
Burlington, Canada). Total RNA extraction from PBMC was 
performed with miRNeasy mini kit following manufacturer’s 
protocol (Qiagen GmbH, Hilden, Germany). cRNA preparation, 
samples hybridization, and scanning were performed following 
the Affymetrix (Affymetrix, Santa Clara, CA, USA) provided 
protocols, by Cogentech Affymetrix microarray unit (Campus 
IFOM IEO, Milan, Italy). All samples were hybridized on Human 
Clariom D (Affymetrix) gene chip and were analyzed using the 
Transcriptome Analysis Console (TAC) 4.0 software (Applied 
Biosystem, Foster City, CA USA by Thermo Fisher Scientific, 
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Waltham, MA, USA). The Signal Space Transformation (SST)-
Robust Multi-Array Average algorithm (RMA) were applied 
to background-adjust, normalize, and log-transform signals 
intensity.
Relative gene expression levels of each transcript were vali da-
ted applying a one-way analysis of variance (ANOVA) (p ≤ 0.01) 
and multiple testing correction. Genes that displayed an expres-
sion level at least 1.5 fold different in the test sample versus 
control sample (p ≤  0.01) were submitted both to functional 
classification, using the Gene Ontology (GO) annotations, and 
to Pathway analysis, employing the Panther expression analysis 
tools1 (21). The enrichment of all pathways and functional classes 
associated to the differentially expressed genes compared to the 
distribution of genes included on the Clariom D microarray was 
analyzed and p values ≤0.05, calculated by the binomial statisti-
cal test, were considered as significant enrichment.
Protein–Protein interaction (PPi) network 
construction and network clustering
The Search Tool for the Retrieval of Interacting Genes (STRING 
version 10.52) is a web-based database which comprises experi-
mental as well as predicted interaction and covers >1,100 
completely sequenced organisms (22). DEGs were mapped to the 
STRING database to detect protein–protein interactions (PPI) 
pairs that were validated by experimental studies (23) and the 
corresponding PPI network was constructed. A score of ≥0.7 for 
each PPI pair was selected to design the PPI network.
To detect high-flow areas (highly connected regions) of the 
network, we used the CFinder software tool, based on the Clique 
Percolation Method (CPM) (24). Finally, Cytoscape software (25) 
was used to define the topology of the built networks.
cell-Free microrna expression  
in ssc sera
To isolate cell-free circulating miRNA (cf-miRNA) in serum, 
we used miRNeasy serum/plasma kit (Qiagen, GmbH, Hilden, 
Germany). For all the samples, RNA was extracted from 200 µL of 
serum in accordance with manufacturer’s instructions. In order 
to minimize the technical variation between samples in down-
stream PCR analysis we added, for all isolations, 0.90 fmol of 
spike-in non-human synthetic miRNA cel-39-3p into the sample 
after the addition of the lysis/denaturant buffer to the serum. 
After extraction, RNA was eluted in 14 µL of nuclease-free water.
Mature miRNA expression was assayed by TaqMan® Advanced 
miRNA assays chemistry (Applied Biosystems, Foster City, CA, 
USA). Briefly, 2 µL of serum RNA was reverse transcribed and 
pre-amplified with TaqMan® Advanced miRNA cDNA synthesis 
kit following manufacturer’s instructions (Applied Biosystems, 
Foster City, CA, USA). Pre-amplified cDNA was diluted 1/10 in 
nuclease-free water and 5 µL of diluted cDNA for each replicate 
were loaded in PCR. 20  µL PCR reactions were composed by 
2× Fast Advanced Master Mix and TaqMan® Advanced miRNA 
assays for hsa-miR-126-3p (477887_mir), hsa-miR-21-5p 
1 http://pantherdb.org/.
2 http://string-db.org/.
(477975_mir), hsa-miR-92a-3p (477827_mir), hsa-miR-155a-5p 
(477927_mir), and hsa-miR-16-5p (477860_mir). Since estab-
lished consensus house-keeping miRNAs for data normalization 
are lacking for serum miRNAs, we used cel-39-3p expression 
(478293_mir) to normalize miRNA expression. Real time PCR 
were carried out in triplicate on a QuantStudio 6 Flex instrument 
(Applied Biosystems, Foster City, CA, USA). Expression values 
were obtained by ΔCt method using QuantStudio Real-time PCR 
system software v. 1.3.
resUlTs
gene array analysis
In order to gain new insights into the pathogenesis of SSc, 
we compared the gene expression profiles of PBMC samples 
obtained from 10 lSSc and 10 dSSc patients with 10 PBMC sam-
ples obtained from age and sex matched healthy donors. Raw data 
have been deposited in the ArrayExpress database at EMBL-EBI3 
under accession number E-MTAB-6531.
When we analyzed lSSc samples, we found that 829 differently 
expressed genes (DEGs) satisfied the Bonferroni-corrected p value 
criterion (p ≤ 0.01) and the fold change criterion (FC ≥  |1.5|), 
displaying robust and statistically significant variation between 
SSc and healthy controls samples. In particular, 736 and 93 
transcripts resulted to be over- and underexpressed, respectively. 
The complete list of modulated genes can be found in Table S1 in 
Supplementary Material.
When the same Bonferroni-corrected p value and fold change 
criteria were used, 456 transcripts were differentially modulated 
in dSSc patients compared to healthy controls, 327 and 129 tran-
scripts resulted to be up- and downregulated, respectively (Table 
S2 in Supplementary Material).
The Gene Ontology analysis of modulated genes in lSSc 
patients, showed that a large number of the modulated transcripts 
can be ascribed to biological processes that may play a role in 
SSc, including: apoptotic process, cell proliferation, growth fac-
tor and growth factor binding, inflammatory response, immune 
response, angiogenesis, endothelial cell activation, cell adhesion, 
and extracellular matrix organization process.
Moreover, a large number of modulated genes were ascribed to 
well-known signaling pathways encompassing Type I interferon, 
epidermal growth factor (EGF) receptor, transforming growth 
factor (TGF)-beta, interleukin, Wnt, glycolysis, platelet derived 
growth factor (PDGF), FAS, and Phosphoinositide 3 (PI3)-kinase 
signaling pathway.
Table 2 shows a selection of DEGs within the above-mentioned 
categories and also includes public gene accession numbers and 
fold changes.
Among genes involved in apoptosis, we found the upregulation 
of B-cell lymphoma 2 (BCL2); BCL2-like 1 (BCL2L1); BCL2-like 
13 (BCL2L13); mitochondrial fission factor (MFF); translocase of 
inner mitochondrial membrane 50 homolog (TIMM50), and zinc 
finger and BTB domain containing 16 (ZBTB16). Interestingly, 
3 www.ebi.ac.uk/arrayexpress.
Table 2 | Selection of modulated genes in lSSc patients versus healthy controls.
iD gene symbol Description Fold change p-Value Public gene iDs
inflammatory response
TC0400011053.hg.1 CXCL10 Chemokine (C­X­C motif) ligand 10 5.20 0.0043 NM_001565
TC1100009225.hg.1 CXCR5 Chemokine (C­X­C motif) receptor 5 2.54 0.0036 NM_001716
TC1100008341.hg.1 FOLR2 Folate receptor 2 1.90 0.0065 NM_000803
TC0200008675.hg.1 IL18RAP Interleukin 18 receptor accessory protein ­2.13 0.0027 NM_003853
TC1000009691.hg.1 IL2RA Interleukin 2 receptor, alpha 2.35 0.0010 NM_000417
TC1900009297.hg.1 TBXA2R Thromboxane A2 receptor 1.72 0.0043 NM_001060
TC0300011059.hg.1 GPX1 Glutathione peroxidase 1 1.81 0.0016 NM_000581
apoptotic process
TC1800008891.hg.1 BCL2 B­cell CLL/lymphoma 2 2.73 0.0012 NM_000633
TC2000008815.hg.1 BCL2L1 BCL2­like 1 1.71 0.0100 NM_001191
TC2200006521.hg.1 BCL2L13 BCL2­like 13 (apoptosis facilitator) 1.83 0.0076 NM_001270726
TC0200010972.hg.1 MFF Mitochondrial fission factor 1.78 0.0012 NM_001277061
TC1900011729.hg.1 TIMM50 Translocase of inner mitochondrial membrane 50 homolog 2.12 <0.0001 NM_001001563
TC1100009101.hg.1 ZBTB16 Zinc finger and BTB domain containing 16 2.04 0.0033 NM_001018011
immune response
TC0800006746.hg.1 BLK BLK proto­oncogene, Src family tyrosine kinase 2.60 0.0060 NM_001715
TC1900008166.hg.1 CD79A CD79a molecule 3.45 0.0008 NM_001783
TC0600011491.hg.1 HLA­DRB5 Major histocompatibility complex, class II, DR β 5 44.50 0.0022 NM_002125
TC1400010492.hg.1 IGHV4­28 Immunoglobulin heavy variable 4­28 14.36 0.0076 AM233776.1
TC1400010806.hg.1 IGHV5­51 Immunoglobulin heavy variable 5­51 9.27 0.0001 FN550293.1
TS00000553.hg.1 IGKV1­27 Immunoglobulin kappa variable 1­27 12.72 0.0016 DQ101172.1
TC0200008384.hg.1 IGKV2D­29 Immunoglobulin kappa variable 2D­29 4.21 0.0030 DQ101153.1
TC2200006771.hg.1 IGLV1­50 Immunoglobulin lambda variable 1­50 4.80 0.0150 FM206563.1
TC1600007312.hg.1 IL4R Interleukin 4 receptor 3.02 <0.0001 NM_000418
TC1600011368.hg.1 LAT Linker for activation of T­cells 2.50 0.0001 NM_001014987
TC2200009231.hg.1 MIF Macrophage migration inhibitory factor 2.27 0.0005 NM_002415
TC1100007771.hg.1 MS4A1 Membrane­spanning 4­domains, subfamily A, 1 2.33 0.0080 NM_021950
TC0300007067.hg.1 MYD88 Myeloid differentiation primary response 88 2.20 0.0008 NM_001172566
TC2200008183.hg.1 VPREB3 Pre­B lymphocyte 3 2.42 0.0090 NM_013378
TC0300013859.hg.1 CD200 CD200 molecule 4.02 <0.0001 NM_001004196
angiogenesis
TC1500010429.hg.1 CIB1 Calcium and integrin binding 1 (calmyrin) 2.56 <0.0001 NM_001277764
TC1700012274.hg.1 ITGB3 Integrin beta 3 4.29 0.0030 NM_000212
TC0700009977.hg.1 PDGFA Platelet­derived growth factor alpha polypeptide 1.70 0.0041 NM_002607
TC1700008661.hg.1 PRKCA Protein kinase C, alpha 1.73 0.0012 NM_002737
endothelial cell activation
TC0400011053.hg.1 CXCL10 Chemokine (C­X­C motif) ligand 10 5.24 0.0050 NM_001565
TC0300011485.hg.1 FOXP1 Forkhead box P1 1.61 0.0070 NM_001012505
TC1400008684.hg.1 PRMT5 Protein arginine methyltransferase 5 1.78 <0.0001 NM_001039619
TC0100016357.hg.1 SELP Selectin P 2.66 0.0039 NM_003005
cell adhesion
TC1100006494.hg.1 CD151 CD151 molecule 1.52 0.0010 NM_001039490
TC1700011435.hg.1 ICAM2 Intercellular adhesion molecule 2 1.56 0.0046 NM_000873
TC1300009165.hg.1 PCDH9 Protocadherin 9 1.62 0.0028 NM_020403
TC1700012274.hg.1 ITGB3 Integrin beta 3 4.29 0.0024 NM_000212
TC1200010794.hg.1 ITGB7 Integrin beta 7 2.10 0.0050 NM_000889
extracellular matrix organization
TC0100010863.hg.1 LAMC1 Laminin, gamma 1 (formerly LAMB2) 2.06 0.0074 NM_002293
TC0600008462.hg.1 COL19A1 Collagen, type XIX, alpha 1 2.94 0.0012 NM_001858
TC2000008678.hg.1 CST3 Cystatin C 2.27 0.0030 NM_000099
TC0600006873.hg.1 BMP6 Bone morphogenetic protein 6 2.83 0.0023 NM_001718
TC0500012519.hg.1 SPARC Secreted protein, acidic, cysteine­rich 3.56 0.0012 NM_001309443
cell proliferation
TC0800008845.hg.1 MYC MYC proto­oncogene, bHLH transcription factor 2.05 0.0065 NM_002467
TC1900010696.hg.1 AKT2 v­Akt murine thymoma viral oncogene homolog 2 2.36 <0.0001 NM_001243027
TC0600007862.hg.1 PIM1 Pim­1 proto­oncogene, serine/threonine kinase 2.15 0.0122 NM_001243186
TC0200015887.hg.1 CUL3 Cullin 3 ­1.54 0.0008 NM_001257197
TC0600011809.hg.1 CCND3 Cyclin D3 1.93 <0.0001 NM_001136017
TC1400010085.hg.1 TCL1A T­cell leukemia/lymphoma 1 A 6.87 <0.0001 NM_001098725
(Continued )
4
Dolcino et al. SSc and Cancer Share Gene Signatures
Frontiers in Immunology | www.frontiersin.org March 2018 | Volume 9 | Article 449
iD gene symbol Description Fold change p-Value Public gene iDs
growth factor and growth factor binding
TC0700009977.hg.1 PDGFA Platelet­derived growth factor alpha polypeptide 1.66 0.0013 NM_002607
TC0300007067.hg.1 MYD88 Myeloid differentiation primary response 88 2.04 0.0004 NM_001172566
TC0600006873.hg.1 BMP6 Bone morphogenetic protein 6 2.92 0.0041 NM_001718
Type i interferon signaling pathway
TC0100015921.hg.1 ADAR Adenosine deaminase, RNA­specific 1.84 0.0001 NM_001025107
TC0600007530.hg.1 HLA­E Major histocompatibility complex, class I, E 1.72 0.0003 NM_005516
TC0600007487.hg.1 HLA­G Major histocompatibility complex, class I, G 1.94 0.0015 NM_002127
TC0100013445.hg.1 IFI6 Interferon, alpha­inducible protein 6 1.83 0.0066 NM_002038
TC1400010584.hg.1 IRF9 Interferon regulatory factor 9 1.82 0.0031 NM_006084
TC1500008232.hg.1 ISG20 Interferon stimulated exonuclease gene 20 kDa 2.52 0.0001 NM_001303233
TC0300007067.hg.1 MYD88 Myeloid differentiation primary response 88 2.13 0.0006 NM_001172566
TC1200012708.hg.1 OAS1 2­5­Oligoadenylate synthetase 1 2.46 0.0108 NM_001032409
TC1200010908.hg.1 STAT2 Signal transducer and activator of transcription 2 1.58 0.0028 NM_005419
TC0400011053.hg.1 CXCL10 Chemokine (C­X­C motif) ligand 10 5.23 0.0040 NM_001565
TC1400010721.hg.1 PSME2 Proteasome activator subunit 2; microRNA 7703 1.70 0.0010 NM_002818
epidermal growth factor receptor signaling pathway
TC1900010696.hg.1 AKT2 v­Akt murine thymoma viral oncogene homolog 2 2.37 <0.0001 NM_001243027
TC1900006864.hg.1 MAP2K7 Mitogen­activated protein kinase kinase 7 2.24 0.0041 NM_001297555
TC0200008742.hg.1 NCK2 NCK adaptor protein 2 2.54 <0.0001 NM_001004720
TC1200009071.hg.1 PEBP1 Phosphatidylethanolamine binding protein 1 1.68 0.0007 NM_002567
Transforming growth factor-beta signaling pathway
TC0600006873.hg.1 BMP6 Bone morphogenetic protein 6 2.91 0.0023 NM_001718
TC0600013126.hg.1 PTPRK Protein tyrosine phosphatase, receptor type, K 3.07 0.0033 NM_001291983
TC1600009200.hg.1 TRAP1 TNF receptor­associated protein 1 1.96 0.0050 NM_001272049
TC1900011636.hg.1 UBE2M Ubiquitin­conjugating enzyme E2M 1.73 0.0046 NM_003969
interleukin signaling pathway
TC1000009691.hg.1 IL2RA Interleukin 2 receptor, alpha 2.46 0.0010 NM_000417
TC1600007312.hg.1 IL4R Interleukin 4 receptor 2.94 <0.0001 NM_000418
TC0800008845.hg.1 MYC MYC proto­oncogene, bHLH transcription factor 2.13 0.0065 NM_002467
TC0 × 00010196.hg.1 RPS6KA6 Ribosomal protein S6 kinase, 90 kDa, polypeptide 6 2.02 0.0012 NM_014496
TC1200010908.hg.1 STAT2 Signal transducer and activator of transcription 2 1.54 0.0022 NM_005419
Wnt signaling pathway
TC1900009240.hg.1 GNG7 Guanine nucleotide binding protein, gamma 7 2.42 0.0010 NM_052847
TC0800008845.hg.1 MYC MYC proto­oncogene, bHLH transcription factor 2.16 0.0066 NM_002467
TC1800007805.hg.1 NFATC1 Nuclear factor of activated T­cells, 1 2.02 0.0042 NM_001278669
TC0300012807.hg.1 SIAH2 Siah E3 ubiquitin protein ligase 2 1.94 0.0011 NM_005067
TC1900009176.hg.1 TCF3 Transcription factor 3 1.93 0.0032 NM_001136139
TC0900010543.hg.1 TLE1 Transducin­like enhancer of split 1 [E(sp1) homolog] 2.13 0.0012 NM_001303103
glycolysis
TC1000007891.hg.1 HK1 Hexokinase 1 1.91 0.0011 NM_000188
TC2100007355.hg.1 PFKL Phosphofructokinase, liver 1.86 0.0030 NM_001002021
TC1500009952.hg.1 PKM Pyruvate kinase, muscle 1.63 0.005 NM_001206796
TC1200006649.hg.1 TPI1 Triosephosphate isomerase 1 1.54 0.0029 NM_000365
Platelet derived growth factor (PDgF) signaling pathway
TC1900010696.hg.1 AKT2 v­Akt murine thymoma viral oncogene homolog 2 2.34 <0.0001 NM_001243027
TC0 × 00009069.hg.1 ARHGAP6 Rho GTPase activating protein 6 2.54 0.0052 NM_001287242
TC0800008845.hg.1 MYC MYC proto­oncogene, bHLH transcription factor 2.05 0.0080 NM_002467
TC0200008742.hg.1 NCK2 NCK adaptor protein 2 2.53 <0.0001 NM_001004720
TC0700009977.hg.1 PDGFA Platelet­derived growth factor alpha polypeptide 1.52 0.0027 NM_002607
Fas signaling pathway
TC1900010696.hg.1 AKT2 v­Akt murine thymoma viral oncogene homolog 2 2.32 <0.0001 NM_001243027
TC0800009239.hg.1 CYC1 Cytochrome c­1 1.81 0.0066 NM_001916
TC0900012167.hg.1 GSN Gelsolin 1.66 0.0041 NM_000177
TC0100017528.hg.1 PARP1 Poly(ADP­ribose) polymerase 1 1.72 0.0012 NM_001618
TC0300007454.hg.1 PARP3 Poly(ADP­ribose) polymerase family member 3 2.05 0.0010 NM_001003931
Phosphoinositide 3 kinase signaling pathway
TC1900010696.hg.1 AKT2 v­Akt murine thymoma viral oncogene homolog 2 2.40 <0.0001 NM_001243027
TC1300008688.hg.1 FOXO1 Forkhead box O1 2.03 0.0008 NM_002015
TC1500009452.hg.1 GNB5 Guanine nucleotide binding protein (G protein), β5 1.65 0.0023 NM_006578
TC1100008136.hg.1 RPS6KB2 Ribosomal protein S6 kinase, 70 kDa, polypeptide 2 1.72 0.0010 NM_003952
Table 2 | Continued
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Table 3 | Pathways enriched in genes modulated in lSSc samples.
Panther pathways p-Value
Apoptosis signaling pathway (P00006) <0.01
Glycolysis (P00024) <0.01
Platelet derived growth factor signaling pathway (P00047) <0.01
5HT4 type receptor mediated signaling pathway (P04376) 0.01
FAS signaling pathway (P00020) 0.01
Histamine H2 receptor mediated signaling pathway (P04386) 0.01
Serine glycine biosynthesis (P02776) 0.02
Beta3 adrenergic receptor signaling pathway (P04379) 0.02
Angiotensin II­stimulated signaling through G proteins and beta­
arrestin (P05911)
0.03
Interleukin signaling pathway (P00036) 0.05
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TIMM50 is an anti-apoptotic gene that has been involved in 
breast cancer cell proliferation (26).
The upregulation of apoptotic molecules was paralleled by the 
overexpression of genes involved in cell proliferation including 
MYC proto-oncogene, bHLH transcription factor (MYC); v-akt 
murine thymoma viral oncogene homolog 2 (AKT2); Pim-1 
proto-oncogene, serine/threonine kinase (PIM); cyclin D3 
(CCND3), and T-cell leukemia/lymphoma 1 A (TCL1A).
Interestingly, all these molecules have been previously asso-
ciated to different type of cancer (27–30). Moreover, we found 
downregulation for cullin 3 (CUL3) a tumor suppressor molecule 
(31). All these observations may suggest that a dysregulation of 
proliferative genes in patients with SSc may predispose to the 
development of malignancies.
We also found upregulation of growth factors encoding mol-
ecules such as platelet-derived growth factor alpha polypeptide 
(PDGFA), bone morphogenetic factor 6 (BM6), and myeloid 
differentiation primary response 88 (MYD88) a fibrogenic mol-
ecule that controls pericyte migration and trans-differentiation of 
endothelial cells to myofibroblasts (32).
Chronic inflammation is a feature of SSc; therefore, the 
upregulation of genes involved in the inflammatory response, 
including chemokine (C-X-C motif) ligand 10 (CXCL10), 
chemokine (C-X-C motif) receptor 5 (CXCR5), folate receptor 
2 (FOLR2), interleukin 2 receptor, alpha (IL2RA), thromboxane 
A2 receptor (TBXA2R), and glutathione peroxidase 1 (GPX1), is 
not surprising.
Scleroderma, like other autoimmune connective tissue diseases, 
is characterized by immune system alterations and the results of 
our analysis also highlighted this aspect, showing a modulation of 
a large number of genes involved in immune response. A selec-
tion of these molecules is reported in Table 2 and includes: BLK 
proto-oncogene, Src family tyrosine kinase; CD79a molecule, 
immunoglobulin-associated alpha (CD79A); major histocompat-
ibility complex, class II, DR beta 5 (HLA-DRB5); immunoglobulin 
heavy variable 4-28 (IGHV4-28); immunoglobulin heavy variable 
5-51 (IGHV5-51); (IGKV1-27); immunoglobulin kappa variable 
2D-29; immunoglobulin lambda variable 1-50 (IGLV1-50); inter-
leukin 4 receptor (IL4R), linker for activation of T-cells (LAT); 
macrophage migration inhibitory factor (MIF); membrane-
spanning 4-domains, subfamily A, member 1 (MS4A1); myeloid 
differentiation primary response 88 (MYD88); pre-B lympho-
cyte 3 (VPREB3), and CD200 molecule (CD200). Among the 
abovementioned molecules, MIF has been described as a lung 
metastasis inducer (33) and CD200 has been involved in the 
development of breast cancer metastasis (34) and of myeloid 
leukemia (35).
The initial stages of SSc are accompanied by an angiogenic 
response to tissue ischemia and vascular damage, that is later 
replaced by a deficient wound healing and by fibrosis (36). 
Indeed, several genes involved in angiogenesis were upregulated 
in lSSc samples including calcium and integrin binding 1 (CIB1); 
integrin beta 3 (ITGB3), platelet-derived growth factor alpha 
polypeptide (PDGFA), and protein kinase C, alpha (PRKCA). 
Interestingly, PDGF stimulates tumor cells, promotes angiogen-
esis, and the development of cancer associated fibroblasts (37) 
leading to tumor progression. In addition, aberrant expression of 
PKCA is associated with a range of malignancies and has recently 
become a target for anti-cancer therapies (38).
The upregulation of genes such as chemokine (C-X-C motif) 
ligand 10 (CXCL10), forkhead box P1(FOXP1), protein arginine 
methyltransferase 5(PRMT5), and selectin P (SELP) is consistent 
with the endothelial cells activation that is typical of SSc and is 
accompanied by the overexpression of cell adhesion molecules 
involved in endothelial cells and leukocytes interactions as well 
as in blood cells extravasation. We indeed found upregulation 
for intercellular adhesion molecule 2 (ICAM2), protocadherin 9 
(PCDH9), integrin beta 3 (ITGB3), integrin beta 7 (ITGB7), and 
CD151 molecule that, importantly, is an emerging possible poor 
prognostic factor for solid tumors (39).
Systemic sclerosis is characterized by connective tissue 
fibrosis of skin and internal organs that is sustained by extracel-
lular matrix (ECM) remodeling (40). Accordingly, we found 
an increased expression of transcripts that play a role in ECM 
organization including laminin gamma 1 (LAMC1), collagen, 
type XIX (COL19A1), bone morphogenetic protein 6 (BMP6), 
cystatin C (CST3), and secreted protein, acidic, cysteine-rich 
(SPARC), a secreted protein that is overexpressed in the fibro-
blasts of skin biopsy from patients with SSc (41). Noteworthy, 
remodeling of the stromal ECM by cancer-associated fibroblasts 
is crucial for tumor cell migration and invasion (42) and SPARC 
has been associated to these events (43). Interestingly, an elevated 
preoperative CST3 level was demonstrated to be related with 
worse survival in patients with renal cell carcinoma (44).
The pathway enrichment analysis that we performed to find 
signaling network that were overrepresented by modulated genes 
in lSSc samples, showed an enrichment in apoptosis, glycolysis, 
PDGF, 5HT4 type receptor, Fas cell surface death receptor 
(FAS), histamine H2 receptor, serine glycine biosynthesis, beta 
3 adrenergic receptor, angiotensin (through G proteins and beta-
arrestin), and interleukin signaling pathways (Table 3).
Interestingly, several of the abovementioned enriched path-
ways are involved in cancer development.
Other modulated transcripts belong to the epidermal growth 
factor (EGF), transforming growth factor (TGF) beta, Wnt, and 
PI3 kinase signalings, all involved not only in the development 
of the SSc associated fibrosis (45, 46) but also in cancer develop-
ment (47–50). In particular, we observed overexpression of the 
AKT2 member of the EGF signaling pathway and of the FOXO1 
component of the PI3K pathway. The deregulation of these genes 
Table 4 | Selection of modulated genes in diffuse SSc patients versus healthy controls.
iD gene symbol Description Fold change p-Value Public gene iDs
apoptosis
TC1500008231.hg.1 AEN Apoptosis enhancing nuclease 2.04 0.0024 NM_022767
TC1800008891.hg.1 BCL2 B­cell CLL/lymphoma 2 1.90 0.0090 NM_000633
TC1600009992.hg.1 BCL7C B­cell CLL/lymphoma 7 C 1.56 0.0101 NM_001286526
TC0200015242.hg.1 STAT1 Signal transducer and activator of transcription 1 2.40 0.0042 NM_007315
TC1900011729.hg.1 TIMM50 Translocase of inner mitochondrial membrane 50 1.76 0.0024 NM_001001563
TC0900009242.hg.1 TRAF2 TNF receptor­associated factor 2 1.52 0.0089 NM_021138
cell proliferation
TC0300009916.hg.1 HES1 Hes family bHLH transcription factor 1 2.03 <0.0001 NM_005524
TC0900007863.hg.1 CKS2 CDC28 protein kinase regulatory subunit 2 1.50 0.0066 NM_001827
TC0200015887.hg.1 CUL3 Cullin 3 ­1.94 0.0068 NM_001257197
TC0600011809.hg.1 CCND3 Cyclin D3 1.56 0.0007 NM_001136017
TC0800008845.hg.1 MYC MYC proto­oncogene, bHLH transcription factor 2.09 0.0072 NM_002467
TC1900010696.hg.1 AKT2 v­Akt murine thymoma viral oncogene homolog 2 1.96 0.0012 NM_001243027
TC0600007862.hg.1 PIM1 Pim­1 proto­oncogene, serine/threonine kinase 2.12 0.0012 NM_001243186
growth factor and growth factor binding
TC1900011707.hg.1 GPI Glucose­6­phosphate isomerase 1.82 0.0016 NM_000175
TC0300007067.hg.1 MYD88 Myeloid differentiation primary response 88 2.50 <0.0001 NM_001172566
TC1100011258.hg.1 FIBP Fibroblast growth factor intracellular binding protein 1.70 0.0092 NM_004214
inflammatory response
TC0400011053.hg.1 CXCL10 Chemokine (C­X­C motif) ligand 10 6.69 0.0001 NM_001565
TC0400011054.hg.1 CXCL11 Chemokine (C­X­C motif) ligand 11 2.01 0.0023 NM_001302123
TC1100009225.hg.1 CXCR5 Chemokine (C­X­C motif) receptor 5 3.31 0.0066 NM_001716
TC0 × 00009667.hg.1 FCGR1B Fc fragment of IgG, high affinity Ib, receptor (CD64) 2.52 0.0076 NM_001004340
TC1400009239.hg.1 FCGR3A Fc fragment of IgG, low affinity IIIa, receptor (CD16a) 2.00 0.0012 NM_000569
TC1600011368.hg.1 LAT Linker for activation of T­cells 1.80 0.0042 NM_001014987
TC1900009134.hg.1 PTGER4 Prostaglandin E receptor 4 (subtype EP4) 2.11 0.0020 NM_000958
immune response
TC1700009612.hg.1 CD79B CD79b molecule immunoglobulin­associated beta 2.80 0.0020 NM_000626
TC1100011888.hg.1 CR2 Complement component receptor 2 1.90 0.0015 NM_001006658
TC1900011707.hg.1 FOXP3 Forkhead box P3 2.01 0.0066 NM_001114377
TC0600007530.hg.1 HLA­A Major histocompatibility complex, class I, A 2.11 0.0002 NM_001242758
TC0600007487.hg.1 HLA­B Major histocompatibility complex, class I, B 1.54 0.0022 D83043.1
TC1700012468.hg.1 HLA­E Major histocompatibility complex, class I, E 1.66 0.0034 NM_005516
TC1700007931.hg.1 HLA­G Major histocompatibility complex, class I, G 1.52 0.0045 NM_002127
TC1100008330.hg.1 IGHV3­66 Immunoglobulin heavy variable 3­66 3.50 0.0060 EU667609.1
TC1600007312.hg.1 IGHV4­61 Immunoglobulin heavy variable 4­61 3.51 0.0027 FN550331.1
TC1400010584.hg.1 IL4R Interleukin 4 receptor 2.02 <0.0001 NM_000418
TC1500008668.hg.1 LAT Linker for activation of T­cells 1.97 0.0011 NM_001014987
TC1100013178.hg.1 LST1 Leukocyte specific transcript 1 2.11 0.0052 NM_007161
TC1200008920.hg.1 MYD88 Myeloid differentiation primary response 88 2.09 0.0006 NM_001172566
TC1900011255.hg.1 RSAD2 Radical S­adenosyl methionine domain containing 2 8.34 0.0001 NM_080657
TC1000008236.hg.1 TAP1 Transporter 1, ATP­binding cassette, sub­family B 2.00 0.0017 NM_001292022
angiogenesis
TC1500010429.hg.1 CIB1 Calcium and integrin binding 1 (calmyrin) 2.08 0.0008 NM_001277764
TC1900011707.hg.1 GPI Glucose­6­phosphate isomerase 1.50 0.0022 NM_000175
TC1700012468.hg.1 HN1 Hematological and neurological expressed 1 2.15 0.0001 NM_001002032
TC0700011770.hg.1 KRIT1 KRIT1, ankyrin repeat containing −2.03 0.0054 NM_001013406
endothelial cell activation
TC1100009225.hg.1 CXCL10 Chemokine (C­X­C motif) ligand 10 5.94 0.0004 NM_001565
TC0600006967.hg.1 EDN1 Endothelin 1 2.23 0.0042 NM_001168319
(Continued )
7
Dolcino et al. SSc and Cancer Share Gene Signatures
Frontiers in Immunology | www.frontiersin.org March 2018 | Volume 9 | Article 449
has been associated with tumor progression and metastatic 
spread (29, 51).
The functional classification of DEGs in dSSc samples shows 
that they reflects the gene modulation observed in lSSC samples 
(see Table 4).
The apoptosis functional class accounted for several upregulated 
transcripts namely apoptosis enhancing nuclease (AEN), B-cell 
CLL/lymphoma 2 (BCL2), B-cell CLL/lymphoma 7 C (BCL7C), 
signal transducer and activator of transcription 1 (STAT1), TNF 
receptor-associated factor 2 (TRAF2), and translocase of inner 
iD gene symbol Description Fold change p-Value Public gene iDs
extracellular matrix organization
TC1900006470.hg.1 BSG Basigin 2.05 0.0022 NM_001728
TC2000008678.hg.1 CST3 Cystatin C 2.13 0.0014 NM_000099
TC0800010204.hg.1 ADAM2 ADAM metallopeptidase domain 2 1.56 0.0084 NM_001278114
Type i interferon signaling pathway
TC0100015921.hg.1 ADAR Adenosine deaminase, RNA­specific 1.94 0.0006 NM_001025107
TC1700007931.hg.1 IFI35 Interferon­induced protein 35 1.70 0.0053 NM_005533
TC0100013445.hg.1 IFI6 Interferon, alpha­inducible protein 6 4.00 <0.0001 NM_002038
TC1000008400.hg.1 IFIT1 Interferon­induced protein with tetratricopeptide repeats 1 7.03 0.0030 NM_001270927
TC1000008396.hg.1 IFIT2 Interferon­induced protein with tetratricopeptide repeats 2 13.27 <0.0001 NM_001547
TC1000008397.hg.1 IFIT3 Interferon­induced protein with tetratricopeptide repeats 3 18.12 0.0010 NM_001031683
TC1100009657.hg.1 IFITM3 Interferon induced transmembrane protein 3 2.11 0.0008 NM_021034
TC0500012017.hg.1 IRF1 Interferon regulatory factor 1 1.73 0.0063 NM_002198
TC1400010584.hg.1 IRF9 Interferon regulatory factor 9 1.80 0.0007 NM_006084
TC0100006483.hg.1 ISG15 ISG15 ubiquitin­like modifier 2.36 0.0011 NM_005101
TC1500008232.hg.1 ISG20 Interferon stimulated exonuclease gene 20 kDa 2.00 0.0021 NM_001303233
TC0300007067.hg.1 MYD88 Myeloid differentiation primary response 88 2.27 0.0001 NM_001172566
TC1200012708.hg.1 OAS1 2­5­oligoadenylate synthetase 1 3.95 0.0004 NM_001032409
TC0200016402.hg.1 RSAD2 Radical S­adenosyl methionine domain containing 2 8.23 0.0003 NM_080657
ras protein signal transduction
TC0700007367.hg.1 DBNL Drebrin­like 2.02 0.0027 NM_001014436
TC0300007432.hg.1 MAPKAPK3 Mitogen­activated protein kinase(PK)­activated PK 3 1.94 0.0031 NM_001243925
TC1600011368.hg.1 LAT Linker for activation of T­cells 1.76 0.0020 NM_001014987
TC2200008641.hg.1 RAC2 Rho family, small GTP binding protein Rac2 1.88 0.0066 NM_002872
TC0100018463.hg.1 RHOC Ras homolog family member C 2.59 0.0041 NM_001042678
p53 pathway
TC2100008385.hg.1 SUMO3 Small ubiquitin­like modifier 3 2.44 0.0031 NM_001286416
TC1900007688.hg.1 CCNE1 Cyclin E1 1.70 0.0066 NM_001238
TC0900009242.hg.1 TRAF2 TNF receptor­associated factor 2 1.73 0.0043 NM_021138
TC1900010696.hg.1 AKT2 v­akt murine thymoma viral oncogene homolog 2 1.77 0.0002 NM_001243027
TC1900007688.hg.1 CCNE1 Cyclin E1 1.83 0.0027 NM_001238
JaK-sTaT cascade
TC0300007256.hg.1 CCR2 Chemokine (C­C motif) receptor 2 −3.18 0.0080 NM_001123041
TC0300009916.hg.1 HES1 Hes family bHLH transcription factor 1 2.08 0.0011 NM_005524
TC1200010908.hg.1 STAT2 Signal transducer and activator of transcription 2 2.04 0.0010 NM_005419
TC0200015242.hg.1 STAT1 Signal transducer and activator of transcription 1 2.56 0.0034 NM_007315
Wnt signaling pathway
TC1400006718.hg.1 PSME1 Proteasome activator subunit 1 2.00 0.0013 NM_001281528
TC0600014110.hg.1 PSMB9 Proteasome subunit beta 9 2.40 0.0001 NM_002800
TC1400010721.hg.1 PSME2 Proteasome activator subunit 2; microRNA 7703 2.66 0.0001 NM_002818
TC1400007320.hg.1 DACT1 Disheveled­binding antagonist of beta­catenin 1 4.54 0.0007 NM_001079520
TC0800008845.hg.1 MYC MYC proto­oncogene, bHLH transcription factor 2.61 0.0076 NM_002467
TC1000008942.hg.1 TCF7L2 Transcription factor 7­like 2 (T­cell specific, HMG­box) 1.76 0.0081 NM_001146274
glycolysis
TC1900011707.hg.1 GPI Glucose­6­phosphate isomerase 1.60 0.0015 NM_000175
TC1200006649.hg.1 TPI1 Triosephosphate isomerase 1 2.00 0.0005 NM_000365
TC2100007355.hg.1 PFKL Phosphofructokinase, liver 2.01 <0.0001 NM_001002021
Platelet derived growth factor signaling pathway
TC1000007761.hg.1 ARID5B AT rich interactive domain 5B (MRF1­like) 2.50 0.0033 NM_001244638
TC0800008845.hg.1 MYC MYC proto­oncogene, bHLH transcription factor 2.43 0.0086 NM_002467
TC0300007432.hg.1 MAPKAPK3 Mitogen­activated protein kinase(PK)­activated PK 3 2.05 0.0032 NM_001243925
TC1900010696.hg.1 AKT2 v­Akt murine thymoma viral oncogene homolog 2 1.97 0.0001 NM_001243027
interleukin signaling pathway
TC1200010908.hg.1 STAT2 Signal transducer and activator of transcription 2 1.54 0.0002 NM_005419
TC0200015242.hg.1 STAT1 Signal transducer and activator of transcription 1 2.27 0.0012 NM_007315
TC0800008845.hg.1 MYC MYC proto­oncogene, bHLH transcription factor 2.12 0.0078 NM_002467
TC1600007312.hg.1 IL4R Interleukin 4 receptor 1.92 0.0001 NM_000418
(Continued )
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Table 5 | Pathways enriched in genes modulated in diffuse SSc samples.
Panther pathways p-Value
Glycolysis (P00024) 0.005
Apoptosis signaling pathway (P00006) 0.006
Inflammation mediated by chemokine and cytokine signaling pathway 
(P00031)
0.008
Cell cycle (P00013) 0.009
Ras pathway (P04393) 0.010
Oxidative stress response (P00046) 0.012
p53 pathway (P00059) 0.018
Ubiquitin proteasome pathway (P00060) 0.020
Interleukin signaling pathway (P00036) 0.026
JAK/STAT signaling pathway (P00038) 0.030
p38 MAPK pathway (P05918) 0.032
Angiogenesis (P00005) 0.035
Epidermal growth factor receptor signaling pathway (P00018) 0.044
iD gene symbol Description Fold change p-Value Public gene iDs
p38 signaling pathway
TC2200008641.hg.1 RAC2 Rho family, small GTP binding protein Rac2 1.71 0.0054 NM_002872
TC1700008757.hg.1 MAP2K6 Mitogen­activated protein kinase kinase 6 −1.66 0.0042 NM_002758
TC0300007432.hg.1 MAPKAPK3 Mitogen­activated protein kinase(PK)­activated PK 3 1.92 0.0077 NM_001243925
epidermal growth factor receptor signaling pathway
TC0200007446.hg.1 PRKCE Protein kinase C, epsilon 1.58 0.0020 NM_005400
TC2200008641.hg.1 RAC2 Rho family, small GTP binding protein Rac2 1.82 0.0031 NM_002872
TC1200010908.hg.1 STAT2 Signal transducer and activator of transcription 2 1.80 0.0003 NM_005419
TC0200015242.hg.1 STAT1 Signal transducer and activator of transcription 1 2.53 0.0042 NM_007315
TC1900010696.hg.1 AKT2 v­Akt murine thymoma viral oncogene homolog 2 2.06 0.0006 NM_001243027
Table 4 | Continued
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mitochondrial membrane 50 homolog (TIMM50). In addition to 
genes that were also modulated in lSSc samples (i.e., MYC, AKT2, 
and PIM1), other genes involved in cell proliferation and also in 
tumor development were overexpressed. These genes include: 
hes family bHLH transcription factor 1(HES1), CDC28 protein 
kinase regulatory subunit 2 (CKS2), and cyclin D3 (CCND3) 
(52–54). Moreover, three upregulated transcripts were ascribed 
to the growth factor binding gene category: glucose-6-phosphate 
isomerase (GPI), fibroblast growth factor intracellular binding 
protein (FIBP), and MYD88 (also modulated in lSSc samples 
as mentioned above). Noteworthy, also in dSSc samples, we 
observed the down-modulation of the tumor suppressor CUL3.
Several modulated genes encode for inflammatory molecules 
including chemokine (C-X-C motif) ligand 11 (CXCL11), Fc 
fragment of IgG, high affinity Ib, receptor (FCGR1B), Fc fragment 
of IgG, low affinity IIIa, receptor (FCGR3A), linker for activation 
of T-cells (LAT), prostaglandin E receptor 4 (PTGER4), CXCL10, 
and CXCR5. These last two transcripts were also overexpressed 
in lSSc samples.
Genes involved in the immune response were modulated also 
in dSSc samples and, besides the genes overexpressed in lSSc 
samples (i.e., IL4R, LAT, and MYD88), we found upregulation 
of CD79b molecule, immunoglobulin-associated beta (CD79B), 
complement component receptor 2 (CR2), forkhead box P3 
(FOXP3), major histocompatibility complex, class I, A (HLA-A), 
major histocompatibility complex, class I, B (HLA-B), major 
histocompatibility complex, class I, E (HLA-E), major histocom-
patibility complex, class I, G (HLA-G), immunoglobulin heavy 
variable 3-66 (IGHV3-66), immunoglobulin heavy variable 4-61 
(IGHV4-61), radical S-adenosyl methionine domain containing 
2 (RSAD2), and transporter 1, ATP-binding cassette, sub-family 
B (TAP1).
Among DEGs involved in angiogenesis there are: glucose-
6-phosphate isomerase (GPI), hematological and neurological 
expressed 1 (HN1), KRIT1, ankyrin repeat containing (KRIT1) 
and CIB1 (also modulated in lSSc samples).
Endothelial activation was well represented in dSSc samples 
by the overexpression of gene encoding for endothelin 1 (EDN1) 
that is associated with diseases characterized by endothelial 
dysfunction and fibrosis (55).
Finally, we found upregulation of three transcripts that play a 
role in the ECM organization including ADAM metallopeptidase 
domain 2 (ADAM2), CST3 (increased also in lSSc samples), and 
basigin (BSG). BSG, also named ECM metalloproteinase inducer 
(EMMPRIN), is expressed on the surface of tumor cells and 
induces fibroblasts to synthesize matrix metalloproteinases (56).
Pathways enrichment analysis showed that pathways also 
overrepresented in lSSc samples were enriched in dSSc samples 
(i.e., glycolysis, apoptosis, and interleukin signaling pathway). 
Besides these signaling pathways, we found an enrichment in 
pathways involved in tumor development including: inflamma-
tion mediated by chemokine and cytokine, cell cycle, Ras (57), 
oxidative stress response (58), p53 (59), ubiquitin proteasome 
(60), JAK/STAT (61), p38 MAPK (62), angiogenesis, and EGF 
receptor signaling pathway (Table 5). Among modulated genes 
belonging to these pathways, we mention ras homolog family 
member C (RHOC), the overexpression of which indicates poor 
prognosis in breast cancer cells (63), and the abovementioned 
AKT2 and HES1.
As found in lSSc samples, among other DEGs involved in 
signal transduction, several transcripts were involved in Wnt, 
PDGF, and type I interferon signaling pathway and, their role in 
cancer development has been already stressed in our dissection 
of genes modulated in lSSc. Not surprisingly, type I interferon 
pathway accounted for a large amount of DEGs (14) and the 
evidence of the modulation of this molecular signaling both in 
lSSc and in dSSc further underlines its role in the pathogenesis 
of the disease.
FigUre 1 | Network analysis of modulated genes in systemic sclerosis (SSc) patients. Protein–protein interaction network of differently expressed genes  
in lSSc (a) and in diffuse cutaneous SSc (b) samples.
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network analysis of Modulated genes  
in ssc
The gene expression profiling of SSc patients was complemented 
with a network analysis. With this purpose, by a bioinforma-
tic analysis, we selected all the functional and experimentally 
validated interactions between the protein products of modula ted 
genes and we constructed the two protein–protein interaction 
(PPI) networks that were representative of lSSc and dSSc dataset.
The lSSc-PPI network comprised 440 genes (nodes) and 
1351 pairs of interactions (edges) (Figure 1A), whereas the dSSc 
included 225 genes and 870 pairs of interactions (Figure 1B).
The PPI networks were then submitted to a modular analysis 
to find set of highly interconnected nodes (modules) that par-
ticipate in multiple activities in a coordinated manner and that 
are expected to play a prominent role in the development of 
biological phenomena.
In the lSSc-PPI network, we identified nine modules that 
are graphically represented in Figure 2. Moreover, a functional 
enrichment analysis was applied to find the associations between 
each module and relevant enriched “GO terms” and pathways. 
All the significantly enriched (p  <  0.05) biological processes 
(BPs) and pathways in each module are showed in Table S3 in 
Supplementary Material and Table  6 shows a selection of the 
most relevant terms. We observed that the most enriched BPs in 
module M0, were the signaling of G-protein coupled receptors 
(GPCRs) and mediated by chemokine. Interestingly, the GPCRs 
pathway is involved in cancer initiation and progression and 
GPCRs are emerging as anti-cancer drug targets (64). In the same 
module M0, we could highlight, among other, an enrichment in 
inflammation mediated by chemokine and cytokine, PI3 kinase 
and endothelin signaling pathway. Module M1 showed an enrich-
ment in the positive regulation of type I interferon production 
BP whereas, among different enriched pathways, we found the 
glycolysis pathway and again, the endothelin signaling pathway. 
Module M2 and M4 were the most representative of the type I 
interferon response. In M2, the GO terms associated to the type I 
interferon signaling were the most enriched biological processes, 
followed by terms associated to the innate immune response 
(i.e., innate immune response, defense response to virus, inter-
feron gamma mediate signaling) and to the adaptive immune 
response (i.e., antigen processing and presentation of exogenous 
peptides). Interestingly, the enriched pathways in M2 were related 
to the Jak/Stat and Interleukin signaling, both associated to tumor 
development as previously remarked.
In M4, the most enriched BPs were interferon-gamma- 
mediated signaling pathway and cellular response to interferon-
gamma. Besides the BPs associated to type I interferon response, 
we found an enrichment in terms referred to the lymphocyte-
associated immune response (i.e., regulation of lymphocyte 
activation, regulation of T  cell activation, regulation of T  cell 
proliferation and antigen processing, and presentation of peptide 
antigen via MHC class I and II). Most enriched pathways in M4 
were referred to interferons (alpha, beta and gamma) pathways. 
Interestingly, in M4, we observed an enrichment in the PD-1 
signaling, an immune-inhibitory-checkpoint that acts as crucial 
mediator for the escape phase of cancer immune editing (65). 
Module M3 and M5 were enriched in terms related to translation 
and other metabolic processes of proteins and, in module M6 the 
FigUre 2 | Modular analysis of the lSSc­protein–protein interaction network. Modules originated from the interaction network of modulated genes in lSSc samples.
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most enriched BPs and pathways were referred to the glycolytic 
pathway. In module M7, we observed an enrichment of many BPs 
associated to positive and negative regulation of apoptosis and con-
cordantly, an enrichment in the apoptotic FAS and p53 pathways 
signaling. Moreover, in M7, several cancer-associated signaling 
pathways were included, including PI3 kinase, Ras, Interleukin, 
FGF, and EGF receptors signaling pathways. Finally, in module 
M8, the protein ubiquitination BP and the ubiquitin proteasome 
pathway were the most over-represented. Interestingly, tumor 
cells have a high dependency on the proteasome for survive and 
proteasome deregulation is frequently induced by many types of 
tumors (66).
From the dSSC-PPI network, we could extract seven modules 
(Figure 3) that were studied by a functional enrichment analysis. 
The results of this analysis are fully presented in Table S4 in 
Supplementary Material and the most relevant terms are showed 
in Table 7.
The BPs that we found enriched in the module M0 were 
mainly referred to the immune response. In particular, we 
observed an enrichment in the regulation of tumor necrosis 
factor superfamily cytokine production process. Moreover, the 
over-represented pathways in M0 reassumed nearly all signal-
ings that were enriched in the entire dSSc dataset, including 
inflammation mediated by chemokine and cytokine, JAK/
STAT, p53, oxidative stress response, Ras, interleukin, EGF 
receptor, and angiogenesis signaling pathway. Module M1 was 
largely enriched in ATP and purine ribo/nucleoside metabolic 
processes, whereas M2 was mostly represented by BPs referred 
Table 6 | Most relevant biological processes and pathways enriched in lSSc 
modules.
gene ontology  
biological processes
p Value Panther  
pathways
p Value
M0
G­protein coupled receptor  
signaling pathway
<0.001 inflammation 
mediated  
by chemokine and 
cytokine signaling  
pathway
<0.001
Chemokine­mediated signaling  
pathway
0.010 PI3 kinase pathway 0.013
Endothelin signaling 
pathway
0.020
M1
Positive regulation of type I  
interferon production
0.001 Glycolysis 0.010
Endothelin signaling 
pathway
0.016
M2
Type I interferon  
signaling pathway
<0.001 JAK/STAT signaling 
pathway
0.001
Cellular response  
to type I interferon
<0.001 Interleukin signaling 
pathway
0.026
Response to  
type I interferon
<0.001
Cytokine­mediated signaling pathway <0.001
Innate immune response <0.001
Immune response <0.001
Defense response to virus <0.001
Interferon­gamma­mediated signaling 
pathway
<0.001
Antigen processing and presentation  
of exogenous peptide via MHC class I
0.030
M3
Translation <0.001 None
Protein metabolic process <0.001
rRNA metabolic process 0.033
M4
Interferon­gamma­mediated  
signaling pathway
<0.001 Interferon gamma  
signaling
<0.001
Cellular response to  
interferon­gamma
<0.001 Interferon Signaling <0.001
Response to interferon­gamma <0.001 Interferon alpha/beta 
signaling
<0.001
Type I interferon signaling pathway <0.001 PD­1 signaling <0.001
Cellular response to type I interferon <0.001
Positive regulation of T cell activation <0.001
Response to type I interferon <0.001
Regulation of T cell activation <0.001
Regulation of T cell proliferation 0.001
Regulation of lymphocyte activation 0.027
Antigen processing and presentation  
of exogenous peptide via MHC class I
0.032
Antigen processing and presentation  
of exogenous peptide via MHC class II
0.050
M5
Translation 0.008 None
M6
Glycolysis <0.001 Glycolysis <0.001
Generation of precursor  
metabolites and energy
<0.001 Pyruvate  
metabolism
<0.001
gene ontology  
biological processes
p Value Panther  
pathways
p Value
Monosaccharide metabolic process 0.007
Carbohydrate metabolic process 0.009
M7
Apoptotic process <0.001 Apoptosis  
signaling pathway
<0.001
Programmed cell death <0.001 FAS signaling 
pathway
0.010
Regulation of apoptotic process <0.001 p53 pathway 
feedback loops 2
0.013
Positive regulation of  
apoptotic process
0.008 Phosphoinositide  
3 kinase pathway
0.016
Negative regulation of apoptotic process 0.027 Ras Pathway 0.030
Extrinsic apoptotic signaling pathway 0.033 Interleukin  
signaling pathway
0.035
FGF signaling 
pathway
0.042
Epidermal growth 
factor receptor 
signaling pathway
0.042
M8
Protein ubiquitination <0.001 Ubiquitin 
proteasome 
pathway
0.001
(Continued )
Table 6 | Continued
12
Dolcino et al. SSc and Cancer Share Gene Signatures
Frontiers in Immunology | www.frontiersin.org March 2018 | Volume 9 | Article 449
to the type I interferon signaling followed by BPs involved in 
both innate and adaptive immune response. In addition, DEGs 
in M2 mainly play a role in ubiquitin proteasome, Jak/Stat, 
interleukin, EGF receptor, and PDGF signaling pathways. In 
M3, the most enriched BP was cellular response to TNF and, 
not surprising, the most over-represented pathway was the 
apoptosis signaling. Other pathways, statistically representative 
of module M3 were toll-like receptor (TLR), ubiquitin protea-
some, and p53 pathway. In particular, the enrichment of TLR 
signaling is interesting since it is well known that inducing 
pro-inflammatory cytokines and co-stimulatory molecules, it 
contributes to the development of an excessive inflammatory 
response, leading to both autoimmune disorders and tumor 
growth (67). Module M4 was mostly enriched in G-protein 
coupled receptor signaling, and we also observed enriched 
BPs related to leukocyte/lymphocyte chemotaxis, whereas the 
most over-represented pathway was inflammation mediated by 
chemokine and cytokine signaling pathways. The Wnt signaling 
pathway was preeminent in module M5. In addition, DEGs in 
this module were also primarily involved in the p53 pathway. 
Response to virus was the most representative BP of module 
M6: is worthwhile mentioning that numerous viruses have been 
proposed as possible triggering factors in SSc (68), and indeed, 
it has been estimated that up to a quarter of human tumors are 
connected to infection or infection-associated chronic inflam-
mation (69).
A large number of BPs involved in immune cells activation, 
proliferation, and differentiation and in type I interferon signal-
ing, were prevalent in M6. The over-represented pathways in this 
module were again signalings also involved in cancer and already 
FigUre 3 | Modular analysis of the diffuse SSc (dSSc)­protein–protein interaction network. Modules originated from the interaction network of modulated genes in 
dSSc samples.
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mentioned in this analysis (i.e., p53, interleukin, PDGF, Jak/Stat, 
TLR, Ras, and apoptosis signaling pathway).
Micrornas in ssc sera
Systemic sclerosis is associated with an increased risk of malig-
nancies, and in the present study, we found a modulation of genes 
encoding for molecules that have been previously associated 
to different types of cancers. An important role of miRNAs in 
human cancers is well established (12). The higher incidence of 
cancer in SSc patients prompted us to investigate whether specific 
cancer-related miRNAs could be deregulated in the serum of SSc 
patients as compared to healthy controls.
Since SSc patients are mainly affected by breast, lung, or 
hematological malignancies (70), we selected miRNAs with a 
solid evidence in literature for deregulation in these kind of can-
cers. We focused on miR-155-5p, miR-126-3p, and miR-16-5p. 
Furthermore, we decided to analyze miR-21-5p and miR-92a, 
since they play key roles in many cancers, and to confirm their 
upregulation in our cohort of SSc patients (Table 8). Cell-free 
miRNAs (cf-miRNA) in limited and diffuse SSc and in healthy 
sera was evaluated by real time PCR, as represented in Figure 4. 
A significant higher expression of 4/5 of the miRNAs tested in 
SSc sera was found as compared to healthy controls. miR-126-3p 
expression also showed a trend of upregulation in SSc samples 
although it did not reach statistically significant differences in 
the samples tested compared to controls. Moreover, no signifi-
cant differences between limited and diffuse SSc were found in 
our analysis. miR-21-5p and miR-92a-3p were upregulated, 
Table 8 | Cancer­related miRNAs selected for expression analysis in SSc 
serum.
mirna Modulation  
in cancer
cancer reference
miR-21-5p Upregulated Breast; lung; leukemias (71–73)
miR-92a-3p Upregulated Lung (74, 75)
miR-155-5p Upregulated Breast; lung; leukemias (71, 72, 76)
miR-126-3p Downregulated Breast (72, 77)
miR-16-5p Downregulated Leukemias (78)
gene ontology  
biological processes
p Value Panther pathways p Value
M3
Cellular response to  
tumor necrosis factor
<0.001 Apoptosis  
signaling pathway
0.009
Response to tumor necrosis 
factor
<0.001 Toll­like receptor 
signaling pathway
0.016
Tumor necrosis factor­mediated 
signaling pathway
<0.001 Ubiquitin proteasome 
pathway
0.020
p53 pathway 0.025
M4
G­protein coupled receptor 
signaling pathway
<0.001 Inflammation mediated 
by chemokine and 
cytokine signaling 
pathway
<0.001
T cell chemotaxis <0.001 Heterotrimeric G­protein 
signaling pathway­Gi 
alpha and Gs alpha
0.001
Leukocyte chemotaxis 0.012
Lymphocyte chemotaxis 0.020
M5
Cell–cell signaling by wnt <0.001 Cell cycle <0.001
Wnt signaling pathway <0.001 p53pathway  
feedback loops 2
0.010
Ubiquitin proteasome 
pathway
0.020
p53 pathway 0.022
M6
Response to virus <0.001 Oxidative stress 
response
<0.001
Regulation of lymphocyte 
proliferation
0.001 p53 pathway  
feedback loops 2
<0.001
Alpha­beta T cell differentiation 0.004 Interleukin signaling 
pathway
<0.001
Alpha­beta T cell activation 0.004 PDGF signaling pathway 0.001
Type I interferon signaling 
pathway
0.005 JAK/STAT signaling 
pathway
0.005
Cellular response to type I 
interferon
0.006 Interferon­gamma 
signaling pathway
0.009
Response to type I interferon 0.012 Toll­like receptor 
signaling pathway
0.013
Regulation of type I interferon 
production
0.027 Ras Pathway
Apoptosis  
signaling pathway
0.020
0.028
EGF receptor  
signaling pathway
0.028
Angiogenesis 0.032
Table 7 | Most relevant biological processes and pathways enriched in diffuse 
SSc modules.
gene ontology  
biological processes
p Value Panther pathways p Value
M0
Positive regulation of  
immune system process
<0.001 Inflammation mediated 
by chemokine and 
cytokine signaling 
pathway
0.001
Regulation of immune  
system process
0.001 JAK/STAT signaling 
pathway
0.003
Immune response 0.004 Interferon­gamma 
signaling pathway
0.010
Regulation of tumor necrosis 
factor superfamily cytokine 
production
0.030 p53 pathway  
feedback loops 2
0.013
Negative regulation of  
activated T cell proliferation
0.040 Oxidative stress 
response
0.022
Positive regulation of  
lymphocyte proliferation
0.050 Toll­like receptor 
signaling pathway
0.024
Positive regulation of 
mononuclear cell proliferation
0.050 Ras Pathway 0.026
Interleukin signaling 
pathway
0.030
Epidermal growth  
factor (EGF) receptor 
signaling pathway
0.033
Platelet derived  
growth factor (PDGF) 
signaling pathway
0.040
Angiogenesis 0.050
M1
ATP metabolic process <0.001 None
Purine ribonucleoside 
triphosphate metabolic process
<0.001
Purine nucleoside triphosphate 
metabolic process
<0.001
Purine ribonucleoside 
monophosphate metabolic 
process
<0.001
Purine nucleoside 
monophosphate  
metabolic process
<0.001
Ribonucleoside monophosphate 
metabolic process
<0.001
ATP synthesis coupled  
electron transport
<0.001
M2
Type I interferon signaling 
pathway
<0.001 Ubiquitin proteasome 
pathway
 < 0.001
Cellular response to type I 
interferon
<0.001 JAK/STAT  
signaling pathway
0.011
Response to type I interferon <0.001 Interleukin  
signaling pathway
0.016
Immune system process <0.001 EGF receptor  
signaling pathway
0.043
Interferon­gamma­mediated 
signaling pathway
<0.001 PDGF signaling  
pathway
0.048
Antigen processing and 
presentation of exogenous 
peptide via MHC class I
<0.001
Regulation of immune response <0.001
(Continued )
Table 7 | Continued
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FigUre 4 | Cell­free circulating miRNA expression in systemic sclerosis (SSc) sera. The expression of the indicated miRNAs was evaluated by real­time PCR  
in serum of systemic sclerosis patients (SSc; n = 30) and of healthy controls (Healthy; n = 30). Expression values of mature miRNAs were calculated using the 
comparative ΔCt method and normalized to spike­in cel­39­3p. Histograms represent mean ± SD. p­values (ns = not significant; *p ≤ 0.05; **p ≤ 0.01; 
***p ≤ 0.001) were determined using the Mann–Whitney rank sum test.
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as reported in literature, further supporting the hypothesis 
of their involvement in SSc pathogenesis. To our knowledge, 
upregulation of miR-155-5p and miR-16-5p in SSc sera has not 
been reported yet, and it suggests a role of these miRNAs in the 
disease.
DiscUssiOn
Systemic sclerosis represents a major medical challenge and many 
unmet needs in the treatment of the disease still remain. However, 
advances have been made thanks to the increased understanding 
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of the pathogenesis of SSc and the overall patients’ survival is 
improved.
The increased risk of malignancies in SSc is a major source of 
concern and the identification of risk factors for both disorders 
may have implications for the prognosis and for the treatment.
We therefore wanted to carry out a gene expression profile 
and an epigenetic analysis in scleroderma patients to verify the 
presence of common bases for the development of malignancies 
and SSc.
We have noticed that the functional classes, to which the 
genes modulated in limited and diffuse forms of SSc belong, 
were virtually overlapping and, in both cases, we observed the 
modulation of genes and pathways previously associated with 
malignancy. Although it has been reported a higher incidence 
of some tumors in patients with dSSc than in those with lSSc, 
our data seem to suggest that in both forms of the disease there 
is a genetic modulation that may be linked to the onset of a neo-
plastic transformation. Indeed, from our analysis has emerged 
that the various classes comprising genes potentially linked 
to the pathogenesis of SSc (such as apoptosis, endothelial cell 
activation, extracellular matrix remodeling, immune response, 
and inflammation), include genes that directly participate in the 
development of malignancies or that are involved in pathways 
known to be associated with carcinogenesis.
In this regard, several pathways enriched in lSSc and/or dSSc 
(apoptosis, glycolysis, PDGF, Fas cell surface death receptor, FAS, 
angiogenesis, interleukin, Ras, Jak/Stat, and EGFR signaling 
pathways) are involved in cancer development.
Indeed, altered apoptosis has a crucial role in the induction of 
a malignant phenotype, and it is well known that some oncogenic 
mutations block apoptosis, leading to cancer progression (79). 
Moreover, some cancer cells express FAS ligand (FasL) and the 
activation of FAS pathway may favor immune privilege to tumors 
by inducing apoptosis of anti-tumor lymphocytes (80).
The modulation of genes involved in the glycolytic pathway 
is not surprising, given that upregulation of glycolysis is a well-
documented property of cancers, and this mechanism confers to 
tumor cells a significant growth advantage (81).
Platelet derived growth factors and PDGF receptors have 
substantial role in regulating cell growth during embryonal 
development. An enhancement of PDGF receptor signaling, 
may also sustain tumor cell growth. Moreover, fibroblasts, and 
myofibroblasts of solid tumors stroma express PDGF receptors, 
and PDGF stimulates these cells promoting tumorigenesis (82). 
Noteworthy, PDGF enhances c-myc expression and stimulates 
the c-myc promoter (83). This gene, found overexpressed in 
our lSSc dataset, coordinates cell growth and cell proliferation 
and its deregulation is a near-universal property of primary and 
metastatic cancers (84).
Ras proteins are key elements in malignant transformation; 
moreover, the Jak/stat signaling pathway sustains epithelial 
mesenchymal transition and generates a pro-tumorigenic micro-
environment. The EGF receptor signaling pathway modulates 
migration and survival of cancer cells.
It has been established that inflammation caused by either 
chronic disease or infection is an important risk factor in cancer 
development and that a variety of interleukins are involved in 
both inflammation and carcinogenesis (85). In particular, among 
genes involved in the interleukin signaling pathways that was 
enriched in lSSc modulated genes, we found overexpression of 
the interleukin 2 receptor alpha (IL2RA) gene. The soluble form of 
this molecule is released from neoplastic cells and is expressed on 
the surface of both lymphoid and non-lymphoid cancer cells (86).
Pathway analysis also highlighted the modulation of a large 
number of genes (11) involved in the Type 1 interferon signaling 
pathway. This pathway is a hallmark of many systemic autoim-
mune diseases (87) including SSc (88) and has also been con-
sidered as a “double-edged sword” in cancer. Indeed, in cancer, 
it promotes both T cell responses and a negative feedback lead-
ing to immunosuppression. Tumor cells can take advantage from 
this counter-regulatory effects induced by IFN type I to avoid 
immune cell killing (89).
This suggests that there are multiple points of contact between 
the signaling pathways leading to scleroderma and those that 
predispose to the development of a malignancy. However, these 
pathways may lead to different outcomes in different tissues 
in which they are expressed, and indeed in patients with scle-
roderma, some malignancies are more frequent such as those 
affecting breast, lung, and lymphoid tissue.
Endothelial cell apoptosis is among the first manifestations 
of vasculopathy associated with the development of SSc, and 
fibroblasts activation and proliferation lead to the fibrotic char-
acteristics of the disease. Gene expression profiles obtained from 
the PBMC of patients with SSc indicate an altered modulation of 
genes involved in apoptosis and in cell proliferation that could, at 
tissue level, exert a mitogenic effect on some cellular populations 
or lead to down-modulation of oncosuppressor genes, as sug-
gested by the downregulation of CUL3 (31) in both lSSc and dSSc.
Our data also suggest the presence of a genetic modulation 
that can favor angiogenesis, a common feature associated to the 
development and progression of any type of cancer.
Modulation of many genes involved in the immune response, 
including genes inducible by type I interferon, reflects the strong 
immune system dysregulation associated with excessive antigenic 
stimulation typical of autoimmune diseases. Such dysregulation 
can either induce proliferation of cells of the immune system, 
leading to malignancy in susceptible individuals or modify the 
immune system’s regulatory mechanisms that inhibit the devel-
opment of naturally occurring cancers.
Several modulated genes participate in the remodeling pro-
cess of the extracellular tissue matrix. Excessive deposition of 
ECM promotes the development of fibrosis, hallmark of SSc, and 
the fibrotic and inflammatory processes of the lung have been 
considered the basis for the eventual onset of lung cancer in SSc. 
On the other hand, within these functional classes, we have also 
observed over-expression of metalloproteases (i.e., ADAM2) or 
ECM metalloproteases inducers (i.e., BSG) typically induced by 
several tumor cells (56, 90). Moreover, genes associated with the 
migration of tumor cells such as SPARC (43), a glycoprotein asso-
ciated with ECM, are involved in the development of non-small 
cell lung cancer. Therefore, while ECM deposition and related 
profibrotic events may favor carcinogenesis through different 
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mechanisms such as blocking lymphatic channels and creating 
niches in which carcinogens may eventually accumulate, on the 
other hand, there is a genetic modulation that favors cancer cells 
spreading.
A crucial issue in basic and clinical research is to understand 
gene modulation in terms of biological networks since pro-
teins usually function in protein–protein interacting networks. 
We therefore wanted to dissect meaningful relationships among 
modulated genes in SSc, analyzing the PPI network in which 
their protein products can be involved. Moreover, since it is 
known that the deregulation of protein expression may provoke 
more drastic biological effects when genes/proteins with more 
interacting partners are involved, we focused our attention on 
the most connected genes/proteins that “as a matter of fact” (by 
definition) are included in the network areas called modules. This 
is particularly important when studying gene regulation in cer-
tain diseases in order to identify the molecular pathways that are 
most relevant in disease pathogenesis. The pathway enrichment 
analysis of modulated genes included in the modules confirmed 
the enrichment of signaling pathways (i.e., the aforementioned 
Jak/stat, glycolysis, Ras, PDGF, EGF receptor, Wnt, and type I 
interferon signaling pathways) associated with carcinogenesis in 
both datasets.
The genes participating to these pathways are indeed com-
prised in network areas (modules), whereas gene interactions 
are concentrated and generally underline significant biological 
processes.
These molecular pathways also emerged from our first global 
analysis of the two datasets, but the network analysis further 
underlined their involvement in SSc. Indeed, members of these 
signaling networks are concentrated in modules were the mol-
ecules that are supposed to play a prominent role in shaping the 
typical features of the disease, are positioned.
Another aspect we have investigated is the expression of 
microRNAs in SSc. Altered expression of miRNAs in SSc, as 
well as their involvement in inflammation and fibrosis, has been 
described (14, 91). Similarly, the implication of miRNAs in 
human cancers is well established (12). A fascinating hypothesis 
is that a dysregulated epigenetic control mediated by miRNAs 
in SSc could promote tumorigenesis. Deregulated expression of 
miRNAs has been found in blood of SSc patients and it could exert 
oncogenic effects at distant sites from SSc lesions. Indeed, the 
upregulation of miR-21 and miR-92a in SSc (16, 92) may support 
this hypothesis, since these miRNAs play a role in many tumors, 
repressing important oncosuppressor genes (74, 93). Thus, the 
higher incidence of breast, lung and hematological malignancies 
in SSc patients (70) prompted us to investigate whether specific 
cancer-related miRNAs could be deregulated in the serum of SSc 
patients. We found that miR-21-5p, miR-92a-3p, miR-155-5p, 
and miR-16-5p expression was significantly higher in SSc sera 
compared to healthy controls. miR-21 can play a role in SSc since 
it is also upregulated in SSc fybroblasts and it is implicated in 
TGF-β-regulated fibrosis (17). Interestingly, miR-21 upregulation 
promotes proliferation, migration, and invasion in lung cancer 
(71). Elevated miR-92a levels in serum and in dermal fibroblasts 
of SSc patients have also been reported (16), and this miRNA is 
implicated in angiogenesis and proliferation in lung cancer and it 
can promote leukemogenesis (74, 75). MiR-155-5p expression was 
also increased in SSc sera. Notably, miR-155 was found upregu-
lated in SSc fybroblasts, and it was associated to the progression 
of lung fibrosis in dSSc patients (94, 95). miR-155 upregulation 
also sustains survival and proliferation in hematological disor-
ders and breast cancer (72, 76). We found increased miR-16-5p 
levels in SSc sera despite this miRNA is frequently associated to 
oncosuppressor functions and it is frequently absent in human 
leukemias (78). Since this miRNA inhibits cell proliferation and 
promotes apoptosis (96), it could participate to the apoptotic 
process of endothelial cells, considered the first pathogenic event 
in SSc. A release of miR-16 in the bloodstream from apoptotic 
endothelial cells could explain the increased levels of the miRNA 
in SSc sera. We also decided to evaluate miR-126 in SSc sera 
since it was found downregulated in breast and lung cancer 
(76, 77). Moreover, miR-126 plays an important role in angiogenic 
signaling and in vascular integrity (97), and we found several 
genes involved in angiogenesis upregulated in SSc by microarray 
analysis. We did not find statistically significant differences in 
the miR-126 expression levels between SSc patients and healthy 
controls, although we observed a trend toward upregulation in 
SSc samples. In conclusion, we describe here interesting findings 
on deregulated cancer-related miRNAs in SSc patients. However, 
further studies are needed to elucidate the potential role of these 
miRNA in SSc. In particular, since the levels of circulating micro-
RNAs can be affected by different cell types, interesting points will 
be to elucidate which cells mainly contribute to these circulating 
oncogenic miRNAs and whether they can play an active role in 
the increased tumorigenesis associated to the disease.
Taken together, our data suggest the presence of modulated 
genes and miRNAs that can play a predisposing role in the 
development of malignancies in SSc. The findings of genetic 
and epigenetic features that are shared by SSc and cancer shed 
new light on the pathogenesis of the disease and strengthen 
the idea that autoimmunity plays a central role in the initiation 
and progression of SSc, since the presence or development of 
malignancies is associated with particular autoantibodies. 
These aspects are central to a better risk stratification of patients 
and to develop an individualized precision medicine strategy.
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